Literature DB >> 30288491

Risk-Reducing Options for Women with a Hereditary Breast Cancer Predisposition.

Ismail Jatoi1.   

Abstract

Genetic testing is now widely utilized to identify women with a hereditary predisposition for breast cancer. Women who carry mutations that increase breast cancer risk may consider three options to reduce risk: screening, chemoprevention, and prophylactic surgery. Yet, no randomized trials have specifically assessed the efficacy of these options in mutation carriers. In many developed countries, mammography is regarded as the optimal means of screening for breast cancer in the general population. However, breast MRI is a more sensitive screening tool, and for mutation carriers, any breast cancer screening strategy should incorporate screening with MRI. In randomized trials of women at high risk for developing breast cancer, chemoprevention reduces that risk, but it has not been shown to reduce mortality. Finally, observational studies suggest that, in mutation carriers, prophylactic surgery may reduce the risk of developing breast cancer by 90-95%. There are several prophylactic mastectomy procedures to choose from, and these are generally done in conjunction with breast reconstruction. In this article, we discuss management of women who carry mutations that have been associated with an increased breast cancer risk. Mutation carriers should be informed of the potential risks and benefits of the three available options to reduce breast cancer risk.

Entities:  

Keywords:  Hereditary predisposition; breast cancer; risk-reducing options

Year:  2018        PMID: 30288491      PMCID: PMC6170022          DOI: 10.5152/ejbh.2018.4324

Source DB:  PubMed          Journal:  Eur J Breast Health


  41 in total

Review 1.  Cancer screening.

Authors:  Ismail Jatoi; William F Anderson
Journal:  Curr Probl Surg       Date:  2005-09       Impact factor: 1.909

Review 2.  Breast cancer chemoprevention.

Authors:  Emmanuel M Gabriel; Ismail Jatoi
Journal:  Expert Rev Anticancer Ther       Date:  2012-02       Impact factor: 4.512

3.  Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction.

Authors:  B A M Heemskerk-Gerritsen; C Seynaeve; C J van Asperen; M G E M Ausems; J M Collée; H C van Doorn; E B Gomez Garcia; C M Kets; F E van Leeuwen; H E J Meijers-Heijboer; M J E Mourits; T A M van Os; H F A Vasen; S Verhoef; M A Rookus; M J Hooning
Journal:  J Natl Cancer Inst       Date:  2015-03-18       Impact factor: 13.506

4.  Clinical breast examination: preliminary results from a cluster randomized controlled trial in India.

Authors:  Rengaswamy Sankaranarayanan; Kunnambath Ramadas; Somanathan Thara; Richard Muwonge; Jem Prabhakar; Paul Augustine; Muraleedharan Venugopal; Gopan Anju; Beela Sara Mathew
Journal:  J Natl Cancer Inst       Date:  2011-08-23       Impact factor: 13.506

Review 5.  Assessing women at high risk of breast cancer: a review of risk assessment models.

Authors:  Eitan Amir; Orit C Freedman; Bostjan Seruga; D Gareth Evans
Journal:  J Natl Cancer Inst       Date:  2010-04-28       Impact factor: 13.506

6.  Bilateral Mastectomy for Unilateral Breast Cancer: a Perplexing Trend.

Authors:  Ismail Jatoi
Journal:  Indian J Surg Oncol       Date:  2015-08-01

7.  Breast cancer mortality trends in the United States according to estrogen receptor status and age at diagnosis.

Authors:  Ismail Jatoi; Bingshu E Chen; William F Anderson; Philip S Rosenberg
Journal:  J Clin Oncol       Date:  2007-04-02       Impact factor: 44.544

Review 8.  Breast Cancer Genetics and Indications for Prophylactic Mastectomy.

Authors:  Helen Krontiras; Meagan Farmer; Julie Whatley
Journal:  Surg Clin North Am       Date:  2018-05-30       Impact factor: 2.741

Review 9.  Risk-reducing mastectomy for the prevention of primary breast cancer.

Authors:  Nora E Carbine; Liz Lostumbo; Judi Wallace; Henry Ko
Journal:  Cochrane Database Syst Rev       Date:  2018-04-05

10.  Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial.

Authors:  Anthony B Miller; Claus Wall; Cornelia J Baines; Ping Sun; Teresa To; Steven A Narod
Journal:  BMJ       Date:  2014-02-11
View more
  2 in total

1.  Multidisciplinary management of CDH1 germinal mutation and prophylactic management hereditary lobular breast cancer: A case report.

Authors:  Sara Mirandola; Francesca Pellini; Eleonora Granuzzo; Maya Lorenzi; Beatrice Accordini; Maurizio Ulgelmo; Alessandra Invento; Davide Lombardi; Marina Caldana; Giovanni Paolo Pollini
Journal:  Int J Surg Case Rep       Date:  2019-04-05

2.  A regional population-based hereditary breast cancer screening tool in Italy: First 5-year results.

Authors:  Laura Cortesi; Bruna Baldassarri; Stefano Ferretti; Elisabetta Razzaboni; Mariangela Bella; Lauro Bucchi; Debora Canuti; Pierandrea De Iaco; Giorgio De Santis; Fabio Falcini; Vania Galli; Lea Godino; Maurizio Leoni; Anna Myriam Perrone; Marco Pignatti; Gianni Saguatti; Donatella Santini; Priscilla Sassoli de'Bianchi; Federica Sebastiani; Mario Taffurelli; Giovanni Tazzioli; Daniela Turchetti; Claudio Zamagni; Carlo Naldoni
Journal:  Cancer Med       Date:  2020-02-11       Impact factor: 4.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.